Radient Pharma to partner with Gaur Diagno for distribution of cancer test kits
Through its US-based subsidiary AMDL Diagnostics Inc, Radient Pharmaceuticals Corporation (RPC)'s executive management would be in India from May 20 to May 25, 2010 with the goal accelerating the commercialization of RPC's Onko Sure In Vitro Diagnostic (IVD) cancer test in India through distribution partnerships with Gaur Diagno.
More specifically, RPC's executive management team will be solidifying expanded partnership agreements for the sales and marketing of Onko Sure test kits with Gaur Diagno; and the development of clinical trails for RPC's Combination Immunogene Therapy (CIT) technology with Jaiva Technologies.
Onko Sure is a simple, non invasive, patent pending and regulatory approved in vitro test for use as an aid in early detection of cancer that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP).
CIT is a proprietary, US-patented technology owned by Radient Pharmaceuticals. Used as a cancer therapy and vaccine, CIT both builds the body's immune system and destroys cancers simultaneously. Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of in vitro diagnostic products.
Gaur Diagno is a New Delhi, India based pharmaceutical distributor. Jaiva Technologies is a US-based multinational biotechnology company focused on the research and development, distribution, marketing and sales of promising third party healthcare technology products, including RPC's CIT cancer therapy and vaccine.
GE Healthcare, CardioDx entered into a strategic alliance
GE Healthcare, the healthcare division of GE and CardioDx, a pioneer in cardiovascular genomic diagnostics, have entered into a strategic alliance to advance and co-develop diagnostic technologies to improve the care and management of patients with cardiovascular disease.
Building on the alliance, the GE Healthymagination Fund, a new equity fund that makes investments in highly promising healthcare technology companies, has invested $5 million in CardioDx. The alliance between the two companies aligns with GE's healthymagination initiative that focuses on reducing cost, increasing access and improving quality in healthcare. This marks the first investment for the Healthymagination Fund. Other financial terms were not disclosed.
CardioDx develops genomic tests to aid in the assessment and tailoring of care of individuals with cardiovascular diseases such as Coronary Artery Disease (CAD), Cardiac Arrhythmias and Heart Failure. The strategic tie up between the two businesses combined with expanded capabilities in product research and development will accelerate the development of new high-value integrated technologies for the diagnosis and care of patients with suspected heart disease. This alliance also reflects GE Healthcare is continuing interest in opportunities to combine in vivo and in vitro diagnostic technologies to improve patient care.
|
|
